schizophrenia
Conditions
Interventions
experimental group:Tropisetron combined with Risperidone
Placebo control:Placebo combined with Risperidone
Sponsors
Beijing An'ding Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: (1) outpatient or inpatient patients, aged 18-55 years, gender not limited, junior high school education or above; (2) meet the DSM-IV diagnostic criteria for schizophrenia, with the total course of illness less than or equal to 5 years; (3) risperidone monotherapy is more than or equal to 1 month, and the stable dose is less than or equal to 6mg/d; (4) at least two MCCB tests were found to have cognitive deficits of more than 1.5 standard deviations; (5) non-smokers; (6) normal hearing, no previous hearing system disease; (7) families and patients sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) comorbidity with other mental disorders, severe physical diseases such as metabolism, heart, liver, kidney and nervous system; (2) had a history of alcohol or drug abuse in the past 12 months and dependence in the past 6 months; (3) received MECT within 6 months; (4) people who are known to be allergic to tropisetron; (5) pregnant or lactating women and women of childbearing age who do not intend to use contraception; (6) it is necessary to drive or operate machinery during the test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| MATRICS Consensus Cognitive Battery;prepulse inhibition; | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive and Negative Syndrome Scale;SANS; | — |
Countries
China
Contacts
Public ContactQijing Bo
Outcome results
None listed